Daina Graybosch
Stock Analyst at Leerink Partners
(0.79)
# 3,749
Out of 4,761 analysts
118
Total ratings
34.09%
Success rate
-14.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $89.50 | +32.96% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $0.96 | +108.88% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.49 | +104.92% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $2.61 | +589.66% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $63.75 | -38.82% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.93 | +221.82% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.73 | +1,817.55% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.42 | +604.23% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $1.04 | +5,669.23% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.24 | +301.79% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $11.07 | +243.27% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.68 | +70.90% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $120.01 | +86.65% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.05 | +1,363.41% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $7.41 | +696.22% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.38 | +1,131.88% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.10 | +328.57% | 4 | Feb 25, 2022 |
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $89.50
Upside: +32.96%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $0.96
Upside: +108.88%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.49
Upside: +104.92%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $2.61
Upside: +589.66%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $63.75
Upside: -38.82%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.93
Upside: +221.82%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.73
Upside: +1,817.55%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.42
Upside: +604.23%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $1.04
Upside: +5,669.23%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.24
Upside: +301.79%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $11.07
Upside: +243.27%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.68
Upside: +70.90%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $120.01
Upside: +86.65%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.05
Upside: +1,363.41%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $7.41
Upside: +696.22%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.38
Upside: +1,131.88%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.10
Upside: +328.57%